Xylem Inc.
XYLBusiness Overview
source: coverage-next-full ticker: XYL step: "01" title: Business Overview — Xylem Inc. created: 2026-05-29
Step 01: Business Overview
Company Snapshot
Xylem Inc. is the world's largest pure-play water technology company by market capitalization. The company designs, manufactures, and distributes a broad portfolio of equipment, services, and solutions used in water and wastewater transport, treatment, testing, and efficiency. Post the May 2023 Evoqua acquisition, Xylem serves over 150 countries and generates approximately $8 billion in annual revenue.
Xylem's core value proposition is helping utilities, municipalities, industrial operators, and commercial building owners solve water-related challenges — from moving water through aging infrastructure to treating contaminated water, measuring consumption accurately, and managing water assets intelligently through digital platforms.
Segment Overview
1. Water Infrastructure (~35% of Revenue)
The legacy heart of Xylem. This segment manufactures pumps, mixers, sensors, and treatment equipment for wastewater transport, collection, and treatment. Key products include:
- Flygt submersible pumps and mixers (iconic brand, used in wastewater lift stations globally)
- Sanitaire biological aeration systems for wastewater treatment
- YSI water quality sensors and analytics instruments
- Wedeco UV disinfection systems
- Goulds Water Technology centrifugal pumps (shared with Applied Water)
End markets are predominantly municipal utilities (~70%) and industrial wastewater operators (~30%). Equipment tends to have 10–20+ year asset lives, driving an aftermarket/parts business that provides revenue stability.
2. Applied Water (~20% of Revenue)
Provides pumps, pressure boosting systems, heat exchangers, and flow control equipment for building services, HVAC, irrigation, and industrial process applications. Key brands include Goulds, Bell & Gossett, Lowara, and AC Fire Pump.
End markets are more cyclical than Water Infrastructure, with meaningful commercial construction and industrial capex exposure. However, the installed base generates ongoing maintenance and replacement demand that moderates cyclicality.
3. Measurement & Control Solutions (~25% of Revenue)
Formerly called "Applied Water" — now the digital intelligence segment. The centerpiece is Sensus, a technology platform acquired in 2016 for $1.7B. Sensus provides:
- Advanced Metering Infrastructure (AMI): smart water, electric, and gas meters
- FlexNet: a proprietary communication network for utility meter data
- Analytics software for leak detection, pressure management, and demand forecasting
- Pure Technologies: pipeline condition assessment and infrastructure monitoring (acquired 2018)
This segment has the highest software and recurring revenue content. Smart meter contracts often run 15–20 years as utilities deploy comprehensive AMI networks. The pipeline assessment business generates repeat service revenue tied to regulatory compliance requirements.
4. Water Solutions & Services (~20% of Revenue)
Created from the Evoqua acquisition. Evoqua's business model was fundamentally different from traditional Xylem — instead of selling equipment, Evoqua operates water treatment systems for customers under long-term service contracts (typically 3–10 years) and also provides outsourced water/wastewater treatment services where Xylem operates the facility on behalf of municipalities or industrial customers.
Key service lines:
- Outsourced water/wastewater treatment: Xylem operates treatment plants for industrial companies, municipalities, and institutions under multi-year contracts
- Industrial water management: On-site industrial water treatment for semiconductor, pharmaceutical, power, and food & beverage sectors
- Municipal services: O&M contracts for public utilities seeking to outsource operations
- Products + chemistry: Filtration, disinfection, and specialized water treatment chemicals
The true recurring revenue nature of this segment (contract-based, not equipment-sale-based) distinguishes it from all other Xylem businesses and meaningfully increases revenue quality.
Geographic Distribution
| Region | Revenue Share (Approx.) |
|---|---|
| United States | ~50% |
| Europe | ~35% |
| Emerging Markets | ~10% |
| Rest of World | ~5% |
The European business skews toward Water Infrastructure (pumps for municipal utilities). The US business spans all four segments with particular strength in M&CS (smart metering AMI is predominantly a US phenomenon) and Water Solutions & Services (Evoqua was predominantly US-based). Emerging market exposure is primarily pumps for water supply and sanitation projects.
Revenue Model
Xylem's consolidated revenue model has three components:
- New equipment sales: Capital goods sold to utilities, municipalities, industrial operators
- Aftermarket parts & services: Replacement parts, consumables, maintenance contracts (~40% of revenue across legacy segments)
- Recurring services/SaaS: Evoqua outsourced treatment contracts, AMI software subscriptions, analytics platforms
The combined recurring revenue across all segments (aftermarket + true recurring contracts) represents approximately 40-45% of total revenue, up materially from ~25% pre-Evoqua.
Strategic Positioning
Xylem operates at the intersection of several powerful secular trends:
- Aging water infrastructure requiring replacement and modernization
- Water scarcity driving efficiency investment
- PFAS/emerging contaminant remediation mandates
- Digitalization of utility operations
- Regulatory pressure on industrial water discharge
The company's "Xylem Vue" digital platform and cloud-connected analytics tools aim to create a software-enabled utility management ecosystem that increases switching costs and recurring revenue over time.
Financial Snapshot
source: coverage-next-full ticker: XYL step: "04" title: Financial Snapshot — Xylem Inc. created: 2026-05-29
Step 04: Financial Snapshot
Income Statement Summary (Last 3 Years)
| Metric | FY2022 | FY2023 | FY2024E |
|---|---|---|---|
| Revenue | $5,523M | $7,362M | ~$8,100M |
| YoY Growth | +10.4% | +33.3% (Evoqua) | ~+10% |
| Organic Growth | +10% | +5% | +5–7% |
| Gross Profit | $2,210M | $2,794M | ~$3,120M |
| Gross Margin | 40.0% | 37.9% | ~38.5% |
| Adj. EBITDA | ~$940M | ~$1,150M | ~$1,420M |
| Adj. EBITDA Margin | ~17.0% | ~15.6% | ~17.5% |
| Adj. Operating Income | ~$775M | ~$920M | ~$1,150M |
| Adj. Operating Margin | ~14.0% | ~12.5% | ~14.2% |
| Adj. EPS | ~$3.02 | ~$3.40 | ~$4.10–4.30 |
| GAAP EPS | ~$2.10 | ~$1.50 | ~$2.80 |
Note: FY2023 reflects ~7 months of Evoqua consolidation (May–December 2023). FY2024E estimates reflect full Evoqua year. GAAP EPS in FY2023 is depressed by acquisition-related charges including purchase accounting amortization, transaction costs, and integration expenses estimated at $500–600M combined.
Revenue Bridge: Pre to Post Evoqua
The Evoqua acquisition is the dominant financial story. Pro forma FY2023 revenue (as if Evoqua owned for full year) was approximately $8.0B, implying the combination generates roughly $2.5B incremental annual revenue vs. standalone Xylem.
| Revenue Component | FY2022 | Pro Forma FY2023 | FY2024E |
|---|---|---|---|
| Legacy Xylem | $5,523M | ~$5,800M | ~$6,100M |
| Evoqua (full year basis) | — | ~$2,100M | ~$2,000M |
| Combined | — | ~$7,900M | ~$8,100M |
Margin Analysis
Gross Margin Dynamics
Gross margin declined from ~40% (FY2022) to ~38% (FY2023) due to:
- Evoqua mix dilution: Evoqua's services business carries lower gross margins (~30–32%) than Xylem's equipment/technology businesses (~42–45%)
- Purchase accounting inventory step-up charges (~100–150 bps impact in initial integration period)
- Supply chain cost pressures flowing through cost of goods
Recovery toward 38.5–39.5% in FY2024 reflects Evoqua integration cost synergies (targeted at $140M total) and improved supply chain conditions.
EBITDA Margin Trajectory
| Year | EBITDA Margin | Commentary |
|---|---|---|
| FY2021 | ~17.5% | Pre-Evoqua, peak efficiency |
| FY2022 | ~17.0% | Supply chain headwinds |
| FY2023 | ~15.6% | Evoqua integration costs + dilution |
| FY2024E | ~17.5% | Recovery + synergy capture |
| FY2025E | ~18.5–19.0% | Full synergy run-rate |
| FY2026E | ~19.5–20.0% | Margin maturity target |
Xylem's management target is 22%+ EBITDA margin at the "Xylem of the future" (2026+ horizon), implying approximately 250–400 bps of continued margin expansion from the FY2024 base.
Cost Synergy Program
Xylem targets $140M in annual run-rate cost synergies from the Evoqua integration, phased:
- Year 1 (2023): ~$25M realized
- Year 2 (2024): ~$75M cumulative
- Year 3 (2025): ~$140M full run-rate
Revenue synergies (cross-selling Evoqua services to Xylem utility customers; selling Xylem equipment into Evoqua's services contracts) are targeted at $100M+ but not given in formal guidance due to visibility uncertainty.
Key Adjustments (GAAP to Adjusted)
The gap between GAAP and adjusted metrics is meaningful in FY2023–2024 due to:
- Amortization of acquired intangibles: ~$300–350M annually (Evoqua customer relationships, technology)
- Integration/restructuring costs: ~$150–200M in FY2023, declining to ~$60–80M in FY2024
- Purchase accounting charges: ~$50–75M in FY2023
- Stock-based compensation: ~$60–70M annually
Investors and management focus on adjusted EPS and adjusted EBITDA as operational metrics; the amortization charges are non-cash and do not affect economic earning power.
Capital Expenditures
| Year | CapEx | % of Revenue |
|---|---|---|
| FY2022 | ~$165M | 3.0% |
| FY2023 | ~$250M | 3.4% |
| FY2024E | ~$280–320M | 3.5–4.0% |
Evoqua's services business is slightly more CapEx-intensive than legacy Xylem (Evoqua owns treatment equipment deployed at customer sites), explaining the modest uptick as a percentage of revenue. Management targets maintenance CapEx at 2.5–3.0% of revenue, with the remainder being growth/integration investment.
Free Cash Flow
| Year | FCF | FCF Margin | FCF/Adj. Net Income |
|---|---|---|---|
| FY2022 | ~$550M | 10% | ~95% |
| FY2023 | ~$550M | 7.5% | ~85% |
| FY2024E | ~$750–850M | ~9.5% | ~90%+ |
FY2023 FCF was impacted by acquisition-related cash costs ($150M+) and working capital investment in the combined business. FY2024 should see a normalization toward Xylem's historical ~90–100% FCF/adjusted net income conversion. Management targets FCF conversion at 100%+ of adjusted net income at steady state.
Key Financial Ratios
| Ratio | FY2022 | FY2024E |
|---|---|---|
| EV/EBITDA | ~16x | ~14x (on current price) |
| P/E (Adjusted) | ~28x | ~22–24x |
| P/FCF | ~30x | ~18–20x |
| Net Debt/EBITDA | 0.5x | ~2.5–3.0x |
| Dividend Yield | ~1.0% | ~1.1% |
| ROIC (Adj.) | ~11% | ~9–10% (temporarily diluted) |
The increase in financial leverage (from minimal net debt to ~$3B post-Evoqua) is the most notable near-term concern; Xylem has committed to deleveraging toward 2.0x by end of 2025.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $XYL.